Toggle Main Menu Toggle Search

ePrints

A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors

Lookup NU author(s): Professor Ruth Plummer, Rebecca Perrett, Professor Alan Calvert

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Publication metadata

Author(s): Plummer ER, Vidal L, Perrett RH, Shaw H, Pilkington M, Hanwell J, Temple G, Fong P, Amelsberg A, Calvert AH, de Bono J

Publication type: Article

Journal: Clinical Cancer Research

Year: 2005

Volume: 11

Issue: 24 Part 2 Supplement S

Pages: 8990S-8990S

ISSN (print): 1078-0432

ISSN (electronic): 1557-3265

Notes: Conference: AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics Philadelphia, PA, 14-18 November 2005.


Actions

    Link to this publication


Share